Abstract
Angiotensin II type 1 (AT1) receptor blockers (ARBs), widely used in the treatment of hypertension, have cardiovascular, cerebral, and renal protective effects beyond blood pressure control. In addition to direct end-organ protection, some ARBs have been suggested to improve abnormalities of glucose and lipid metabolisms, resulting in an antiatherosclerotic effect in patients with hypertension. In several clinical trials, the effects of ARBs on lipid metabolism have been emerged, although the effects are heterogeneous. Certain subgroups of ARBs such as telmisartan have been identified as partial agonists for the peroxisome proliferators activated receptor (PPAR)-γ, and thus, this class of ARBs has been mostly focused on their effects on lipid metabolism. Based on the pleiotropic effects on lipid metabolism, we can envision that ARBs would provide the promising outcome for hypertensive patients aggregating metabolic risk factors, including dyslipidemia.
Keywords: ARB, dyslipidemia, lipid metabolism, PPAR-γ
Current Vascular Pharmacology
Title: Pleiotropic Effects of ARB on Dyslipidemia
Volume: 9 Issue: 2
Author(s): Isao Taguchi, Teruo Inoue, Migaku Kikuchi, Shigeru Toyoda, Takuo Arikawa, Shichiro Abe and Koichi Node
Affiliation:
Keywords: ARB, dyslipidemia, lipid metabolism, PPAR-γ
Abstract: Angiotensin II type 1 (AT1) receptor blockers (ARBs), widely used in the treatment of hypertension, have cardiovascular, cerebral, and renal protective effects beyond blood pressure control. In addition to direct end-organ protection, some ARBs have been suggested to improve abnormalities of glucose and lipid metabolisms, resulting in an antiatherosclerotic effect in patients with hypertension. In several clinical trials, the effects of ARBs on lipid metabolism have been emerged, although the effects are heterogeneous. Certain subgroups of ARBs such as telmisartan have been identified as partial agonists for the peroxisome proliferators activated receptor (PPAR)-γ, and thus, this class of ARBs has been mostly focused on their effects on lipid metabolism. Based on the pleiotropic effects on lipid metabolism, we can envision that ARBs would provide the promising outcome for hypertensive patients aggregating metabolic risk factors, including dyslipidemia.
Export Options
About this article
Cite this article as:
Taguchi Isao, Inoue Teruo, Kikuchi Migaku, Toyoda Shigeru, Arikawa Takuo, Abe Shichiro and Node Koichi, Pleiotropic Effects of ARB on Dyslipidemia, Current Vascular Pharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157016111794519336
DOI https://dx.doi.org/10.2174/157016111794519336 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Possible Target of Antioxidative Therapy for Diabetic Vascular Complications-Vascular NAD(P)H Oxidase
Current Medicinal Chemistry Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?
Current Pharmaceutical Design The Role of Heat Shock Protein 90 and Endothelial Nitric Oxide Synthase Signaling in Cardiovascular Therapy
Current Signal Transduction Therapy Editorial:Genomics and Epigenomics of Tumor and Aging Cells
Current Genomics Gastrin-Releasing Peptide Receptor as a Molecular Target for Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot Topic: Recent Developments in Prodrug Design: Drug Targeting, Pharmacological and Pharmacokinetic Improvements Related to a Reduction of Adverse Effects (Guest Editors: Daniela Melisi & Maria Grazia Rimoli)]
Current Topics in Medicinal Chemistry Plasma Steroid Level Measured Using Modern Separation Techniques as Biomarkers in Biological Diagnostics
Current Pharmaceutical Analysis Beneficial Morphofunctional Changes Promoted by Sildenafil in Resistance Vessels in the Angiotensin II-Induced Hypertension Model
Current Pharmaceutical Biotechnology Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Current Topics in Medicinal Chemistry Drug-Drug Interactions Associated with Antiplatelet Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72
Current Immunology Reviews (Discontinued) Physicochemical Characterization and Evaluation of Buccal Adhesive Patches Containing Propranolol Hydrochloride
Current Drug Delivery New Perspectives on Acetaminophen
Current Cardiology Reviews Vascular Endothelium and Hypovolemic Shock
Current Vascular Pharmacology Air Pollution Exposure and Blood Pressure: An Updated Review of the Literature
Current Pharmaceutical Design Repurposing Antihypertensive Drugs for the Management of Alzheimer’s Disease
Current Medicinal Chemistry The Role of Endogenous H2S in Cardiovascular Physiology
Current Pharmaceutical Biotechnology Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity
Current Pharmaceutical Design Subject Index to Volume 4
Current Drug Targets Physical Activity and Hypertension: Evidence of Cross-Sectional Studies,Cohort Studies and Meta-Analysis
Current Hypertension Reviews